A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

*The trial information contained on this page was imported from ClinicalTrials.gov. Click here to view this trial on ClinicalTrials.gov.

Back to search
Print this study
Full Title:
An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants With Relapsed or Refractory Multiple Myeloma
Myeloma stage or condition:
Multiple Myeloma
Study phase:
Phase 1/Phase 2
The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).
Detailed Description:
Not available
Drug : CC-92480

Specified dose on specified days

Drug : Tazemetostat

Specified dose on specified days

Drug : BMS-986158

Specified dose on specified days

Drug : Trametinib

Specified dose on specified days

Drug : Dexamethasone

Specified dose on specified days

Study Arms:
Experimental : Part 1 Arm A: Dose Finding
Experimental : Part 1 Arm B: Dose Finding
Experimental : Part 1 Arm C: Dose Finding
Active Comparator : Part 2 Arm D: Dose Expansion
Experimental : Part 2 Arm E: Dose Expansion
Experimental : Part 2 Arm F: Dose Expansion
Experimental : Part 2 Arm G: Dose Expansion
Study Type:
Study Design:
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Masking: None (Open Label)
Recruitment status:
Eligibility criteria:
Inclusion Criteria:
  • Relapsed or refractory multiple myeloma (MM) and must: 1. have documented disease progression during or after their last myeloma therapy 2. be refractory to, intolerant to, or not a candidate for available, established therapies known to provide clinical benefit in MM
  • Must have measurable disease
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1
  • Agree to follow the CC-92480 Pregnancy Prevention Plan (PPP)
Exclusion Criteria:
  • Known active or history of central nervous system (CNS) involvement of MM
  • Plasma cell leukemia; Waldenstrom's macroglobulinemia; polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome; or clinically significant light-chain amyloidosis.
  • Impaired cardiac function or clinically significant cardiac disease
  • Previous SARS-CoV-2 infection within 14 days for asymptomatic or mild symptomatic infections or 28 days for severe/critical illness prior to Cycle 1 Day 1 (C1D1)
  • For Part 1: received prior therapy with CC-92480
  • For Part 2: received prior therapy with CC-92480, tazemetostat, BMS-986158, or trametinib
  • Previously received allogeneic stem-cell transplant at any time or received autologous stem-cell transplant within 12 weeks of initiating study treatment
  • Received any of the following within 14 days prior to initiating study treatment: 1. Plasmapheresis 2. Major surgery 3. Radiation therapy other than local therapy for myeloma associated bone lesions 4. Use of any systemic anti-myeloma drug therapy
  • Used any investigational agents within 28 days or 5 half-lives (whichever is shorter) prior to initiating study treatment
  • COVID-19 vaccine within 14 days prior to C1D1 Other protocol-defined inclusion/exclusion criteria apply
Locations / Centres:

Alberta Health Services AHS - Foothills Medical Centre FMC, Calgary, Alberta – Recruiting

University of Alberta - Cross Cancer Institute, Edmonton, Alberta – Recruiting

University Health Network UHN - Princess Margaret Hospital PMH, Toronto, Ontario – Recruiting

Name: BMS Study Connect Contact Center www.BMSStudyConnect.com
Phone: 855-907-3286
Email: [email protected]
First posted:
Actual start date:
October 18, 2022
Last updated:
Estimated enrollment:
Estimated completion date:
Estimated primary completion date:
Multiple Myeloma
18 Years-N/A
Accepts healthy volunteers:
Listed location countries:
United Kingdom
United States
NCT number:
Other study ID numbers:
Has Data monitoring committee:
U.S. FDA-regulated product:
IPD Sharing Statement :
Responsible party:
Study sponsor:
Bristol-Myers Squibb
Bristol-Myers Squibb Bristol-Myers Squibb
Protocol Registration and Results System:
Verification date: